Benefit-risk assessment of brensocatib for treatment of non-cystic fibrosis bronchiectasis.

MLA

Chalmers, James D., et al. “Benefit-Risk Assessment of Brensocatib for Treatment of Non-Cystic Fibrosis Bronchiectasis.” ERJ Open Research, vol. 9, no. 3, May 2023. EBSCOhost, https://doi.org/10.1183/23120541.00695-2022.

APA

Chalmers, J. D., Metersky, M. L., Feliciano, J., Fernandez, C., Teper, A., Maes, A., Hassan, M., & Chatterjee, A. (2023). Benefit-risk assessment of brensocatib for treatment of non-cystic fibrosis bronchiectasis. ERJ Open Research, 9(3). https://doi.org/10.1183/23120541.00695-2022

Chicago

Chalmers, James D, Mark L Metersky, Joseph Feliciano, Carlos Fernandez, Ariel Teper, Andrea Maes, Mariam Hassan, and Anjan Chatterjee. 2023. “Benefit-Risk Assessment of Brensocatib for Treatment of Non-Cystic Fibrosis Bronchiectasis.” ERJ Open Research 9 (3). doi:10.1183/23120541.00695-2022.